Law360, New York (October 28, 2009) -- A unit of specialty pharmaceutical firm Watson Pharmaceuticals Inc. has struck a deal with Barr Pharmaceuticals Inc. that resolves patent litigation over Watson’s Oxytrol and grants Barr a license to eventually market a generic version of the overactive bladder treatment.
Watson Laboratories Inc. agreed to settle the infringement suit that it launched in October 2008 in the U.S. District Court for the District of Delaware after Barr filed an abbreviated...
